JP Morgan Chase’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-63,491
Closed -$7K – 6222
2018
Q4
$7K Sell
63,491
-1,810,106
-97% -$1.19M ﹤0.01% 5506
2018
Q3
$3.19M Buy
1,873,597
+93,320
+5% +$167K ﹤0.01% 3110
2018
Q2
$3.1M Sell
1,780,277
-45,989
-3% -$79.5K ﹤0.01% 3070
2018
Q1
$3.34M Sell
1,826,266
-937,272
-34% -$1.98M ﹤0.01% 2906
2017
Q4
$6.16M Sell
2,763,538
-641,839
-19% -$1.6M ﹤0.01% 2512
2017
Q3
$8.82M Buy
3,405,377
+1,417,177
+71% +$4.83M ﹤0.01% 2089
2017
Q2
$8.85M Buy
1,988,200
+752,475
+61% +$3.1M ﹤0.01% 2061
2017
Q1
$5.76M Sell
1,235,725
-42,050
-3% -$244K ﹤0.01% 2337
2016
Q4
$7.78M Sell
1,277,775
-23,169
-2% -$121K ﹤0.01% 2104
2016
Q3
$7.17M Buy
1,300,944
+62,748
+5% +$294K ﹤0.01% 1999
2016
Q2
$4.71M Sell
1,238,196
-65,890
-5% -$223K ﹤0.01% 2335
2016
Q1
$3.6M Buy
1,304,086
+281,991
+28% +$1.02M ﹤0.01% 2390
2015
Q4
$5.79M Sell
1,022,095
-133,225
-12% -$812K ﹤0.01% 2131
2015
Q3
$6.12M Buy
1,155,320
+830,625
+256% +$6.43M ﹤0.01% 2093
2015
Q2
$2.69M Buy
+324,695
New +$1.57M ﹤0.01% 2739
2014
Q4
– Sell
-103,399
Closed -$287K – 4445
2014
Q3
$287K Sell
103,399
-3,779
-4% -$13.7K ﹤0.01% 3874
2014
Q2
$436K Buy
107,178
+59,152
+123% +$251K ﹤0.01% 3162
2014
Q1
$255K Buy
+48,026
New +$269K ﹤0.01% 3342
2013
Q4
– Sell
-21,926
Closed -$98K – 4340
2013
Q3
$98K Sell
21,926
-16,103
-42% -$72.2K ﹤0.01% 4183
2013
Q2
$162K Buy
+38,029
New +$191K ﹤0.01% 4048

Other funds holding SGYP

JP Morgan Chase's SGYP Position: Q1 2019 in Review

JP Morgan Chase sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 63,491 shares — an estimated $7K sold.

JP Morgan Chase first reported a position in SGYP in Q2 2013 and held it in 20 quarters. The position peaked at $8.85M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • JP Morgan Chase reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Chase sold 63,491 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $7K.
  • JP Morgan Chase first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 20 quarters.
  • JP Morgan Chase's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8.85M in Q2 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.